{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:01:25Z","timestamp":1773151285164,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13063-016-1205-8","type":"journal-article","created":{"date-parts":[[2016,2,28]],"date-time":"2016-02-28T23:24:57Z","timestamp":1456701897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["RiMINI \u2013 the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Christian","family":"Schulz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Sch\u00fctte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siegfried","family":"Kropf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedhelm C.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Vasapolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon M.","family":"Kliegis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Riegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Malfertheiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,29]]},"reference":[{"issue":"3","key":"1205_CR1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/jhep.2002.31250","volume":"35","author":"P Ferenci","year":"2002","unstructured":"Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy \u2013 definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35(3):716\u201321.","journal-title":"Hepatology"},{"issue":"2","key":"1205_CR2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.12968\/hmed.2012.73.2.79","volume":"73","author":"D Patel","year":"2012","unstructured":"Patel D, McPhail MJW, Cobbold JFL, Taylor-Robinson SD. Hepatic encephalopathy. Br J Hosp Med (Lond). 2012;73(2):79\u201385.","journal-title":"Br J Hosp Med (Lond)"},{"issue":"5","key":"1205_CR3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/BF01072921","volume":"23","author":"CE Atterbury","year":"1978","unstructured":"Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis. 1978;23(5):398\u2013406.","journal-title":"Am J Dig Dis"},{"issue":"1","key":"1205_CR4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cld.2011.12.003","volume":"16","author":"G Bianchi","year":"2012","unstructured":"Bianchi G, Giovagnoli M, Sasdelli AS, Marchesini G. Hepatic encephalopathy and health-related quality of life. Clin Liver Dis. 2012;16(1):159\u201370.","journal-title":"Clin Liver Dis"},{"issue":"1","key":"1205_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1746-6342.2006.03215.x","volume":"25","author":"FF Poordad","year":"2007","unstructured":"Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25(1):3\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"1205_CR6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2036.2009.04211.x","volume":"31","author":"JS Bajaj","year":"2010","unstructured":"Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther. 2010;31(5):537\u201347.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1205_CR7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/hep.510280108","volume":"28","author":"M Groeneweg","year":"1998","unstructured":"Groeneweg M, Quero JC, de Bruijn I, Hartmann IJ, Essink-bot ML, Hop WC, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998;28(1):45\u20139.","journal-title":"Hepatology"},{"key":"1205_CR8","first-page":"159(8)","volume":"15","author":"KV Kowdley","year":"2013","unstructured":"Kowdley KV, Burmann BE. ACP Journal Club. Adding rifaximin to lactulose increased reversal and decreased mortality in hepatic encephalopathy. Ann Intern Med. 2013;15:159(8).","journal-title":"Ann Intern Med."},{"issue":"2","key":"1205_CR9","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/j.gastro.2010.08.061","volume":"140","author":"JS Bajaj","year":"2011","unstructured":"Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology. 2011;140(2):478\u201387. e1.","journal-title":"Gastroenterology"},{"issue":"3","key":"1205_CR10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccell.2010.04.007","volume":"22","author":"KJ Foster","year":"2010","unstructured":"Foster KJ, Lin S, Turck CJ. Current and emerging strategies for treating hepatic encephalopathy. Crit Care Nurs Clin North Am. 2010;22(3):341\u201350.","journal-title":"Crit Care Nurs Clin North Am"},{"issue":"2","key":"1205_CR11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11011-013-9383-5","volume":"28","author":"KR Patidar","year":"2013","unstructured":"Patidar KR, Bajaj JS. Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis. 2013;28(2):307\u201312. doi: 10.1007\/s11011-013-9383-5 .","journal-title":"Metab Brain Dis"},{"issue":"2","key":"1205_CR12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11011-013-9392-4","volume":"28","author":"P Sharma","year":"2013","unstructured":"Sharma P, Sharma BC. Disaccharides in the treatment of hepatic encephalopathy. Metab Brain Dis. 2013;28(2):313\u201320. doi: 10.1007\/s11011-013-9392-4 .","journal-title":"Metab Brain Dis"},{"issue":"2","key":"1205_CR13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/ajg.2010.455","volume":"106","author":"SS Sidhu","year":"2011","unstructured":"Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol. 2011;106(2):307\u201316.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"1205_CR14","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","volume":"362","author":"NM Bass","year":"2010","unstructured":"Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071\u201381.","journal-title":"N Engl J Med"},{"issue":"9","key":"1205_CR15","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/ajg.2013.219","volume":"108","author":"BC Sharma","year":"2013","unstructured":"Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108(9):1458\u201363.","journal-title":"Am J Gastroenterol"},{"key":"1205_CR16","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/hep.23128","volume":"50","author":"JS Bajaj","year":"2009","unstructured":"Bajaj JS, Saeian K, Schubert CM, Hafeezullah M, Franco J, Varma RR, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009;50:1175\u201383.","journal-title":"Hepatology."},{"key":"1205_CR17","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1016\/j.transproceed.2006.10.107","volume":"38","author":"GW Neff","year":"2006","unstructured":"Neff GW, Kemmer N, Zacharias VC, Kaiser T, Duncan C, McHenry R, et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc. 2006;38:3552\u20135.","journal-title":"Transplant Proc."},{"key":"1205_CR18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.21533","volume":"45","author":"S Prasad","year":"2007","unstructured":"Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology. 2007;45:549\u201359.","journal-title":"Hepatology."},{"issue":"1","key":"1205_CR19","doi-asserted-by":"crossref","first-page":"G168","DOI":"10.1152\/ajpgi.00190.2011","volume":"302","author":"JS Bajaj","year":"2012","unstructured":"Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2012;302(1):G168\u201375.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1205_CR20","unstructured":"ICH-GCP: ICH harmonised tripartite guideline \u2013 guideline for good clinical practice E6 (R1), June 1996. http:\/\/www.ich.org\/products\/guidelines\/efficacy\/efficacy-single\/article\/good-clinical-practice.html ."},{"key":"1205_CR21","unstructured":"WMA Declaration of Helsinki \u2013 ethical principles for medical research involving human subjects, 64th WMA General Assembly, Fortaleza, Brazil, October 2013."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-016-1205-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T03:10:55Z","timestamp":1498273855000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.trialsjournal.com\/content\/17\/1\/111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,29]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1205"],"URL":"https:\/\/doi.org\/10.1186\/s13063-016-1205-8","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,29]]},"article-number":"111"}}